Navigation Links
Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
Date:8/16/2011

SAN DIEGO, Aug. 16, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that its Investigational New Drug (IND) application for ME-143 (formerly NV-143), the Company's lead NADH oxidase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The Company plans to initiate a Phase I clinical trial of intravenous ME-143 by September.

"This IND represents a significant milestone for Marshall Edwards and, more importantly, a critical step forward in the development of a drug candidate that we believe has the potential to significantly improve the treatment of patients with cancer," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are excited to get back into the clinic and are working diligently to initiate a Phase I trial of ME-143 as soon as possible."

ME-143 was derived from an isoflavone technology platform that has generated a number of compounds with anti-proliferative activity against tumor cells in laboratory studies. In pre-clinical studies, ME-143 has demonstrated anti-tumor activity against a number of tumor cell lines, including breast, colorectal and ovarian. In addition to broad single-agent activity, ME-143 has also shown an ability to enhance the cytotoxic effects of chemotherapy in pre-clinical studies.

Marshall Edwards owns exclusive worldwide rights to ME-143.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143 (formerly NV-143). The second is a mitochondrial inhibitor program that includes lead candidate ME-344 (formerly NV-344). The Company expects to initiate a Phase I clinical trial of intravenous ME-143 by September 2011 and submit an Investigational New Drug application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
2. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
3. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
4. Marshall Edwards Announces Private Placement
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Receives Positive Response From NASDAQ
7. Marshall Edwards to Host Annual Meeting of Stockholders
8. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
9. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
10. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... -- Economic growth in the United States will continue in ... in their December 2016 Semiannual Economic Forecast. Expectations are ... in mid-2009, as indicated in the monthly ISM ® ... manufacturing sector is optimistic about growth in 2017, with ... the non-manufacturing sector indicates that 14 of its industries ...
(Date:12/8/2016)... LOS ANGELES , Dec. 8, 2016 /PRNewswire/ ... and manufacturing of dissolution testing and diffusion testing ... has been acquired by Teledyne Instruments, Inc. ("Teledyne"). ... Hanson,s long-proven line of precision testing instruments, as ... while accelerating development of new products and services. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading ... has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE ... Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage Lung ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... Suite 10.2 version gives development continuity to its innovative Unified Instance Manager ... management capacity. In addition, this new version optimizes the unattended auto-dialing system ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... from offices headquartered in Jefferson County, is announcing the launch of a charity ... , The number of homeless women and children in Birmingham has grown steadily ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill Mull Agencies, a Wichita-based ... and around central Kansas, is joining the Youth Horizons organization for a charity ... Headquartered in Wichita, Youth Horizons works to empower area children from unstable, troubled, ...
Breaking Medicine News(10 mins):